These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 10415820

  • 21. Batimastat. BB 94, collagenase inhibitors-1.
    Drugs R D; 1999 Feb; 1(2):139-41. PubMed ID: 10566008
    [No Abstract] [Full Text] [Related]

  • 22. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI, Du MT.
    Drug Des Discov; 2003 Feb; 18(4):123-6. PubMed ID: 15553924
    [Abstract] [Full Text] [Related]

  • 23. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG, Conway JG, Cowan DJ, Gaul M, Glennon K, Lambert MH, Leesnitzer MA, McDougald DL, Moss ML, Musso DL, Rizzolio MC.
    J Med Chem; 2001 Nov 22; 44(24):4252-67. PubMed ID: 11708926
    [Abstract] [Full Text] [Related]

  • 24. The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3.
    Lee MH, Verma V, Maskos K, Becherer JD, Knäuper V, Dodds P, Amour A, Murphy G.
    FEBS Lett; 2002 Jun 05; 520(1-3):102-6. PubMed ID: 12044879
    [Abstract] [Full Text] [Related]

  • 25. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE).
    Milla ME, Leesnitzer MA, Moss ML, Clay WC, Carter HL, Miller AB, Su JL, Lambert MH, Willard DH, Sheeley DM, Kost TA, Burkhart W, Moyer M, Blackburn RK, Pahel GL, Mitchell JL, Hoffman CR, Becherer JD.
    J Biol Chem; 1999 Oct 22; 274(43):30563-70. PubMed ID: 10521439
    [Abstract] [Full Text] [Related]

  • 26. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity.
    Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME.
    Biochemistry; 2002 Jul 30; 41(30):9462-9. PubMed ID: 12135369
    [Abstract] [Full Text] [Related]

  • 27. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
    Xue CB, Chen XT, He X, Roderick J, Corbett RL, Ghavimi B, Liu RQ, Covington MB, Qian M, Ribadeneira MD, Vaddi K, Trzaskos J, Newton RC, Duan JJ, Decicco CP.
    Bioorg Med Chem Lett; 2004 Sep 06; 14(17):4453-9. PubMed ID: 15357971
    [Abstract] [Full Text] [Related]

  • 28. New drugs on the horizon: matrix metalloproteinase inhibitors.
    Rothenberg ML, Nelson AR, Hande KR.
    Stem Cells; 1999 Sep 06; 17(4):237-40. PubMed ID: 10437989
    [No Abstract] [Full Text] [Related]

  • 29. Benzodiazepine inhibitors of the MMPs and TACE.
    Nelson FC, Delos Santos E, Levin JI, Chen JM, Skotnicki JS, DiJoseph JF, Sharr MA, Sung A, Killar LM, Cowling R, Jin G, Roth CE, Albright JD.
    Bioorg Med Chem Lett; 2002 Oct 21; 12(20):2867-70. PubMed ID: 12270165
    [Abstract] [Full Text] [Related]

  • 30. The role of proteolysis in Alzheimer's disease.
    Hooper NM, Trew AJ, Parkin ET, Turner AJ.
    Adv Exp Med Biol; 2000 Oct 21; 477():379-90. PubMed ID: 10849764
    [Abstract] [Full Text] [Related]

  • 31. Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
    Dabrowska A, Giermasz A, Marczak M, Gołab J, Jakóbisiak M.
    Anticancer Res; 2000 Oct 21; 20(1A):391-4. PubMed ID: 10769685
    [Abstract] [Full Text] [Related]

  • 32. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes.
    Borland G, Murphy G, Ager A.
    J Biol Chem; 1999 Jan 29; 274(5):2810-5. PubMed ID: 9915814
    [Abstract] [Full Text] [Related]

  • 33. Partial purification and characterization of a tumor necrosis factor-alpha converting activity.
    Robache-Gallea S, Bruneau JM, Robbe H, Morand V, Capdevila C, Bhatnagar N, Chouaib S, Roman-Roman S.
    Eur J Immunol; 1997 May 29; 27(5):1275-82. PubMed ID: 9174621
    [Abstract] [Full Text] [Related]

  • 34. The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration.
    Mäkelä M, Sorsa T, Uitto VJ, Salo T, Teronen O, Larjava H.
    Adv Dent Res; 1998 Nov 29; 12(2):131-5. PubMed ID: 9972137
    [Abstract] [Full Text] [Related]

  • 35. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
    Lukacova V, Zhang Y, Kroll DM, Raha S, Comez D, Balaz S.
    J Med Chem; 2005 Apr 07; 48(7):2361-70. PubMed ID: 15801829
    [Abstract] [Full Text] [Related]

  • 36. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme.
    Slack BE, Ma LK, Seah CC.
    Biochem J; 2001 Aug 01; 357(Pt 3):787-94. PubMed ID: 11463349
    [Abstract] [Full Text] [Related]

  • 37. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta.
    Nelson KK, Schlöndorff J, Blobel CP.
    Biochem J; 1999 Nov 01; 343 Pt 3(Pt 3):673-80. PubMed ID: 10527948
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
    Barlaam B, Bird TG, Lambert-Van Der Brempt C, Campbell D, Foster SJ, Maciewicz R.
    J Med Chem; 1999 Nov 18; 42(23):4890-908. PubMed ID: 10579851
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.